Lancet (London, England) 2024 Oct 14
Progress in the treatment paradigms for locally advanced cervical cancer.
Related Questions
Is there a subgroup of patients who benefited significantly from a specific protocol?
New comment by Radiation Oncologist at Vanderbilt-Ingram Cancer Center ( March 28, 2025)
Mostly agree - only difference is I would not routinely add Pembro for patients whose only qualifying factor is node-positivity. FDA specifically does not have Pembro approved...